Home » Stocks » ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc. (ACAD)

Stock Price: $39.25 USD -0.99 (-2.45%)
Updated Aug 12, 2020 1:09 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 6.19B
Revenue (ttm) 393.08M
Net Income (ttm) -225.18M
Shares Out 157.68M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $39.25
Previous Close $40.23
Change ($) -0.99
Change (%) -2.45%
Day's Open 40.62
Day's Range 39.11 - 40.95
Day's Volume 1,490,566
52-Week Range 23.77 - 58.72

More Stats

Market Cap 6.19B
Enterprise Value 5.53B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 157.68M
Float 115.43M
EPS (basic) -1.47
EPS (diluted) -1.47
FCF / Share -0.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.82M
Short Ratio 5.15
Short % of Float 11.00%
Beta 1.68
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 15.74
PB Ratio 10.26
Revenue 393.08M
Operating Income -236.84M
Net Income -225.18M
Free Cash Flow -138.60M
Net Cash 658.65M
Net Cash / Share 4.18
Gross Margin 20.12%
Operating Margin -60.25%
Profit Margin -57.30%
FCF Margin -35.26%
ROA -24.10%
ROE -42.81%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (16)

Buy 15
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$59.12*
(50.64% upside)
Low
42.0
Current: $39.25
High
71.0
Target: 59.12
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue33922412517.330.060.121.154.912.0742.14
Revenue Growth51.5%79.19%620.68%28311.48%-49.17%-89.52%-76.67%137.4%-95.09%-
Gross Profit32821111614.260.060.121.154.912.0742.14
Operating Income-247-247-292-273-165-93.23-38.30-20.89-22.8515.09
Net Income-235-245-289-271-164-92.48-37.95-20.85-22.7715.14
Shares Outstanding14712712311610197.2585.7255.1252.1838.59
Earnings Per Share-1.60-1.94-2.36-2.34-1.63-0.95-0.44-0.38-0.440.39
Operating Cash Flow-151-167-218-208-122-66.43-31.77-21.63-19.90-10.70
Capital Expenditures-1.13-2.10-0.81-1.51-2.14-0.18-0.610.25-0.13
Free Cash Flow-152-170-219-210-124-66.61-32.38-21.38-19.90-10.58
Cash & Equivalents70247834453121632218610831.0537.09
Total Debt6.36-------0.030.08
Net Cash / Debt69647834453121632218610831.0237.01
Assets78354038556122232518910932.1138.39
Liabilities84.0561.1249.2242.7422.1315.976.995.958.758.71
Book Value69947933551820030918284.9823.3629.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ACADIA Pharmaceuticals Inc.
Country United States
Employees 570
CEO Stephen R. Davis

Stock Information

Ticker Symbol ACAD
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ACAD
IPO Date May 27, 2004

Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.